Morgan Stanley: 'Big picture this acquisition bolsters GILD's established position in CAR-T in oncology'
Tweet Send to a Friend
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $171.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
